L'Oréal S.A. OR
ParisHousehold and personal productsFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| €B | Dec 31 | Jun 30 |
|---|---|---|
| Cash | 9.9 | 4.0 |
| Securities | 0.0 | 0.0 |
| Debt | 10.1 | 14.3 |
| Net cash | -0.3 | -10.3 |
| Equity | 35.0 | 33.8 |
- Debt / EBITDA
- 1.37×
- Debt / equity
- 0.42×
- Leases (6/30/26)
- €2.4B
- Diluted shares
- 535M
- Book value / share
- €63.29
- Price / book
- 7.0×
- Net cash / share
- −€19.24
- Market cap
- €236.7B
- Enterprise value
- €247.0B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | 5.8% | +4.2 pts | |
| Operating margin | 20.0% | +0.1 pts | |
| FCF margin | 13.1% | +0.9 pts | |
| Capex / revenue | 3.0% | -0.4 pts | |
| Research & Innovation expense | €697M | +4% | |
| Product-dispute expense | €169M | – | |
| Professional Products sales · 9/30/26 | €1.5B | +12% | |
| Professional Products sales excluding IT phasing growth | +14% | – | |
| Consumer Products sales · 9/30/26 | €4.0B | +4% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About OR
L’Oréal sells beauty products through mass retailers, luxury shops, pharmacies, salons and online. Consumer Products and Luxe contributed about 37% and 35% of 2025 sales.
- Brand Trust
L'Oréal Paris and Maybelline retain globally scaled category positions, and L'Oréal Paris grew in double digits in H1 2026.
- Capex Knowhow Scale
Group-wide R&I spans 22 research centres, 13 evaluation centres and more than 4,000 scientists, allowing formulations and launches to be adapted across regions and brands.
- Brand Trust
A portfolio of 27 prestige brands supports broad luxury-beauty participation, and L'Oréal reports global fragrance leadership.
- Contractual Exclusivity
Long-duration exclusive licences secure beauty-development and distribution rights to fashion-house brands.
- Oct 22, 2026
The issuer confirmed completion of the Innovist majority acquisition. It also reported Mexico consumer-product supply disruptions and retailer inventory effects, which contributed to negative regional quarterly adjusted growth; no undisclosed acquisition price or cash amount is inferred.
- Oct 5, 2026
Reuters, citing an unverified Wall Street Journal report, said L’Oréal hired advisers to explore US chemical-related liabilities; no completed transfer or restructuring was announced.
- Sep 24, 2026
L’Oréal priced EUR2bn of bonds for corporate purposes, adding floating and fixed financing with coupons of Euribor plus 27 basis points, 3.75% and 4.00%.
- Sep 24, 2026
BOLD and Nykaa announced a collaboration to take minority stakes in Indian beauty brands, expanding access to local innovation while founders keep control.
- Sep 10, 2026
Arizona filed a consumer-fraud complaint against L’Oréal and its subsidiaries over chemical hair-relaxer marketing, adding a state enforcement case to product litigation; allegations are not a finding of liability.
Ownership
Go deeper on OR
- Compare stock research toolsFundamentals, valuation and screening platforms for OR.19 tools
- See OR's price chartNo price chart here yet. See price history and indicators.17 tools
- Read OR's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (€) | |||||||||||||
| Revenue | 44.14 | 46.18 | 47.84 | 53.08 | 49.84 | 57.68 | 71.16 | 76.69 | 81.12 | 82.28 | 84.82 | +7.2%/yr | |
| Cash flow | 8.33 | 9.22 | 9.40 | 11.13 | 11.49 | 12.02 | 11.68 | 14.16 | 15.46 | 16.17 | 16.81 | +7.6%/yr | |
| Earnings | 5.46 | 6.78 | 6.92 | 6.66 | 6.34 | 8.21 | 10.61 | 11.52 | 11.95 | 11.44 | 11.79 | +8.6%/yr | |
| Free cash flow | 5.97 | 6.98 | 6.88 | 8.94 | 9.76 | 10.10 | 9.18 | 11.39 | 12.39 | 13.38 | 14.11 | +9.4%/yr | |
| Capex | 2.36 | 2.24 | 2.51 | 2.19 | 1.73 | 1.92 | 2.50 | 2.77 | 3.06 | 2.79 | 2.70 | +1.9%/yr | |
| Dividends | 3.09 | 3.30 | 3.56 | 3.87 | 3.87 | 4.05 | 4.84 | 6.05 | 6.65 | 7.05 | 7.25 | +9.6%/yr | |
| Book value | 43.40 | 44.04 | 47.82 | 52.27 | 51.62 | 42.13 | 50.55 | 54.14 | 61.81 | 65.29 | 63.29 | +4.6%/yr | |
| Diluted shares (M) | 565 | 564 | 563 | 563 | 562 | 560 | 538 | 537 | 536 | 535 | 535 | -0.6%/yr | |
| Totals (€B) | |||||||||||||
| Revenue | 24.9 | 26.0 | 26.9 | 29.9 | 28.0 | 32.3 | 38.3 | 41.2 | 43.5 | 44.1 | 45.4 | +6.5%/yr | |
| Operating income | 4.0 | 4.4 | 4.8 | 5.1 | 4.5 | 5.7 | 7.2 | 7.7 | 8.2 | 8.4 | 8.7 | +8.7%/yr | |
| Net income | 3.1 | 3.8 | 3.9 | 3.8 | 3.6 | 4.6 | 5.7 | 6.2 | 6.4 | 6.1 | 6.3 | +7.9%/yr | |
| Free cash flow | 3.4 | 3.9 | 3.9 | 5.0 | 5.5 | 5.7 | 4.9 | 6.1 | 6.6 | 7.2 | 7.5 | +8.7%/yr | |
| Buybacks | 0.5 | 0.5 | 0.5 | 0.7 | 0.0 | 10.1 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | +0.0%/yr | |
| Dividends | 1.7 | 1.9 | 2.0 | 2.2 | 2.2 | 2.3 | 2.6 | 3.2 | 3.6 | 3.8 | 3.9 | +9.0%/yr | |
| Net cash | 0.5 | 1.9 | 2.8 | 4.4 | 5.5 | -1.9 | -1.4 | -2.6 | -2.5 | -0.3 | -10.3 | −€0.7B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 71.6 | 71.7 | 72.8 | 73.0 | 73.1 | 73.9 | 72.4 | 73.9 | 74.2 | 74.3 | 74.4 | +2.7 pts | |
| Operating margin | 15.9 | 16.9 | 17.9 | 17.1 | 16.1 | 17.7 | 18.9 | 18.7 | 19.0 | 19.0 | 19.1 | +3.1 pts | |
| Net margin | 12.4 | 14.7 | 14.5 | 12.6 | 12.7 | 14.2 | 14.9 | 15.0 | 14.7 | 13.9 | 13.9 | +1.5 pts | |
| FCF margin | 13.5 | 15.1 | 14.4 | 16.8 | 19.6 | 17.5 | 12.9 | 14.9 | 15.3 | 16.3 | 16.6 | +2.7 pts | |
| ROIC | 12.4 | 14.4 | 15.0 | 15.4 | 14.4 | 16.9 | 19.0 | 18.3 | 17.4 | 17.9 | 14.8 | +5.5 pts | |
| Return on equity | 12.6 | 15.4 | 14.5 | 12.7 | 12.3 | 19.5 | 21.0 | 21.3 | 19.3 | 17.5 | 18.6 | +5.0 pts | |
| R&D % of revenue | 3.4 | 3.4 | 3.4 | 3.3 | 3.4 | 3.2 | 3.0 | 3.1 | 3.1 | 3.1 | 3.1 | -0.2 pts | |
| Stock pay % of revenue | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | 0.6 | 0.6 | +0.1 pts | |
| Capex % of revenue | 5.4 | 4.9 | 5.3 | 4.1 | 3.5 | 3.3 | 3.5 | 3.6 | 3.8 | 3.4 | 3.2 | -2.0 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Competitive
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Consumer Products Division36.5%2 claims
- L'Oréal Luxe Division35.4%2 claims
- Dermatological Beauty Division16.4%2 claims
- Professional Products Division11.7%1 claim
Moat claims
- Applies to
- Consumer Products Division
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
L'Oréal Paris and Maybelline retain globally scaled category positions, and L'Oréal Paris grew in double digits in H1 2026. An independent 2026 brand valuation ranked L'Oréal second in cosmetics, supporting consumer recognition, while its 13% value decline is live counterevidence against treating leadership as permanent.
Consumer Products adjusted like-for-like sales grew 4.3% in H1 2026, supporting brand demand despite promotional competition and the September hair-relaxer complaint.
- Consumer Products sales€4.0B+4%
- Consumer Products sales excluding IT phasing growth+4%
- Product-dispute expense€169M
- Indie, K-beauty and local brands scaling rapidly through social and e-commerce channels
- Private-label and retailer-owned brands improving quality and value perception
- Reputation shocks from product safety controversies
- SourceArizona consumer-fraud complaint against L’OréalSep 11, 2026
- Source2025 Annual Report - Consumer Products DivisionMar 18, 2026
- SourceBrand Finance Cosmetics 50 2026May 5, 2026
- Applies to
- Consumer Products Division
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
Group-wide R&I spans 22 research centres, 13 evaluation centres and more than 4,000 scientists, allowing formulations and launches to be adapted across regions and brands. Spending, facilities and patent applications demonstrate research capacity, but the company does not disclose returns by launch.
Patent filings rose from 610 in 2023 to 694 in 2024 and 725 in 2025; H1 2026 R&I expense was EUR697.1m, but filings and spending do not establish superior launch returns.
- Research & Innovation expense€697M+4%
- Patents filed725+4%
- Research & Innovation workforce4,311+1%
- Diminishing returns on R&I spend versus nimble challengers
- Ingredient and formulation commoditization
- Regulatory restrictions reducing claims differentiation
- Source2025 Annual Report - worldwide R&I reachMar 18, 2026
- SourceL'Oréal 2026 Half-Year Results - R&I spendingJul 29, 2026
- Applies to
- L'Oréal Luxe Division
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
A portfolio of 27 prestige brands supports broad luxury-beauty participation, and L'Oréal reports global fragrance leadership. Brand Finance independently ranked Lancôme the sector's second-strongest brand in 2026, but also reported weakening familiarity, credibility, appeal and price acceptance. Weaker price acceptance can restrict further premiumisation.
Luxe adjusted like-for-like sales grew 5.1% in H1 2026, while its reported divisional margin fell 20 basis points to 22.1%; recovery supports the portfolio but does not remove premium-pricing pressure.
- Luxe sales€4.2B+6%
- Luxe sales excluding IT phasing growth+7%
- Product-dispute expense€169M
- Luxury demand cyclicality, China exposure and travel-retail volatility
- Brand fatigue and faster trend cycles in prestige makeup
- Counterfeits and gray-market leakage
- Source2025 Annual Report - Luxe leadershipMar 18, 2026
- SourceBrand Finance Cosmetics 50 2026 - LancômeMay 5, 2026
- Applies to
- L'Oréal Luxe Division
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Oct 8, 2026
Long-duration exclusive licences secure beauty-development and distribution rights to fashion-house brands. Bottega Veneta and Balenciaga were consolidated from April 2026; the 50-year Gucci licence is not effective until July 2027 and remains subject to regulatory approvals, so the barrier is contractual rather than current brand ownership.
The completed Kering Beauté purchase adds Creed and two 50-year licences; the July 2026 Gucci agreement secures another 50-year right from July 2027, subject to approval.
- Luxe sales€4.2B+6%
- Luxe sales excluding IT phasing growth+7%
- Regulatory delay, transition failure, non-renewal or later renegotiation on worse terms
- Fashion house vertical integration into beauty
- Reputation spillover from fashion-house controversies
- SourceL'Oréal 2026 Half-Year Results - Gucci licenceJul 29, 2026
- Applies to
- Dermatological Beauty Division
- Confidence
- Durability
- durable
- Trajectory
- wideningas of Oct 8, 2026
The Division reached more than 320,000 healthcare professionals in 2025. Those relationships support recommendation, education, credibility and pharmacy/medical-channel access, although they are not exclusive and consumer discovery is increasingly digital.
Healthcare-professional reach rose from 310,000 in 2024 to more than 320,000 in 2025, and management-defined share rose from 25.5% to 25.8%; H1 2026 adjusted like-for-like sales grew 10.6%.
- Dermatological Beauty sales€1.9B+12%
- Dermatological Beauty sales excluding IT phasing growth+14%
- Healthcare professionals reached≥320,000+3%
- Dermocosmetics market share25.8%+0.3 pts
- Shifts from professional recommendation to influencer-led discovery
- HCP trust erosion from product controversies
- Channel disruption (pharmacy vs. omnichannel competition)
- Source2025 Annual Report - HCP reachMar 18, 2026
- Source2025 Annual Report - dermocosmetics positionMar 18, 2026
- Applies to
- Dermatological Beauty Division
- Confidence
- Durability
- durable
- Trajectory
- wideningas of Oct 8, 2026
La Roche-Posay, CeraVe and SkinCeuticals combine medical-channel presence with consumer recognition. CeraVe's US dermatologist-recommendation claim supports trust, but it is company-reported and overlaps with the HCP network, so professional contact and brand trust can partly reflect the same customer relationships.
Dermatological Beauty adjusted like-for-like sales grew 10.6% in H1 2026 as CeraVe recovered and SkinCeuticals remained strong, supporting broader adoption of its science-led brands.
- Dermatological Beauty sales€1.9B+12%
- Dermatological Beauty sales excluding IT phasing growth+14%
- Dermocosmetics market share25.8%+0.3 pts
- Product-dispute expense€169M
- Brand trust damage from adverse events or unsupported efficacy claims
- Competitor science-backed, prescription-adjacent and K-beauty brands gaining credibility
- Source2025 Annual Report - CeraVe recommendationMar 18, 2026
- Applies to
- Professional Products Division
- Confidence
- Durability
- durable
- Trajectory
- wideningas of Oct 8, 2026
Relationships across 400,000 salons and interactions with over three million hairstylists support professional distribution, education, advocacy and product adoption. The network is large and current, but salons multi-home and 39% of divisional sales now comes from selective retail and e-commerce.
Professional Products adjusted like-for-like sales grew 11.6% in H1 2026 after company-defined share rose from 26% in 2024 to 27% in 2025; Henkel’s Olaplex acquisition raises the competitive test.
- Professional Products sales€1.5B+12%
- Professional Products sales excluding IT phasing growth+14%
- Salons reached400,0000%
- Hairstylists reached≥3,000,0000%
- Professional sales through selective retail and e-commerce39.0%
- Professional beauty market share27.0%+1.0 pts
- Stylists switching brands due to pricing, promotions, or trend shifts
- Direct-to-consumer and selective-retail premium hair brands bypassing salons
- Salon channel weakness in economic downturns
- Source2025 Annual Report - salon reachMar 18, 2026
- Source2025 Annual Report - hairstylist reachMar 18, 2026
Profile change log
- Nov 11, 2026 · business change
The issuer confirmed completion of the Innovist majority acquisition. It also reported Mexico consumer-product supply disruptions and retailer inventory effects, which contributed to negative regional quarterly adjusted growth; no undisclosed acquisition price or cash amount is inferred.
- Oct 8, 2026 · business change
Reuters, citing an unverified Wall Street Journal report, said L’Oréal hired advisers to explore US chemical-related liabilities; no completed transfer or restructuring was announced.
- Oct 8, 2026 · business change
BOLD and Nykaa announced a collaboration to take minority stakes in Indian beauty brands, expanding access to local innovation while founders keep control.
- Oct 8, 2026 · business change
L’Oréal priced EUR2bn of bonds for corporate purposes, adding floating and fixed financing with coupons of Euribor plus 27 basis points, 3.75% and 4.00%.
- Oct 8, 2026 · business change
Arizona filed a consumer-fraud complaint against L’Oréal and its subsidiaries over chemical hair-relaxer marketing, adding a state enforcement case to product litigation; allegations are not a finding of liability.
- Oct 8, 2026 · business change
Henkel completed its Olaplex purchase and claimed the global number-two professional-hair position, increasing competition for L’Oréal’s salon and premium haircare brands.
- Oct 8, 2026 · business change
L’Oréal signed a 50-year exclusive Gucci beauty licence due to start on 1 July 2027, subject to regulatory approvals, securing a long contract while adding transition risk.
- Oct 8, 2026 · business change
L’Oréal agreed to buy a majority stake in Innovist, adding digital Indian personal-care brands if the deal closes.
- Oct 8, 2026 · business change
L’Oréal completed its EUR4bn Kering Beauté purchase, adding Creed and the Balenciaga and Bottega Veneta beauty licences, with consolidation from April.
- Oct 8, 2026 · business change
L’Oréal bought another 10% of Galderma for EUR4.2bn, taking its stake to 20% and changing the investment to equity-method accounting.
- Oct 8, 2026 · business change
L’Oréal completed its EUR2.4bn Aēsop purchase, extending Luxe into premium skincare and branded retail.
- Oct 8, 2026 · business change
L’Oréal sold The Body Shop, removing a retail business and making continuing beauty operations the comparable earnings base.
- Oct 8, 2026 · analyst revision
Verified seven moat claims; added their trajectories, operating KPI histories, capital-allocation debate and management. Replaced interim segment weights with FY2025 sales and removed profit shares that excluded corporate expenses. Classified mass beauty as competitive on current industry evidence; the application score changes from 84.42 to 83.26 while claim strengths and evidence coverage remain unchanged. Matched all four divisions to sourced end markets.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Global mass beauty and personal care
Affordable and premium mass-market skin, hair, makeup, fragrance and personal-hygiene products, including oral care, sold worldwide through supermarkets, drugstores and online. Excludes prestige-only products, prescription treatments and salon labour.
- L’Oréal
- Procter & Gamble
- Unilever
- Beiersdorf
- Coty
- Kao
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| OR | 83 | 74.4% | 19.1% | |
| Industry median | 11 | 69 | 60.6% | 14.8% |
| Sector median | 85 | 74 | 55.3% | 17.0% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Daily replenishment gives this market low overall cyclicality; economic weakness mainly shifts shoppers toward smaller packs, promotions and cheaper brands.
- Rising household income in emerging countries has high influence on new beauty users and premium mass formulas.
- Hair treatments, accessible skincare actives and fast launches support mix, while clinical evidence matters for claims.
- Digital retail and social discovery have high influence on brand trial; retailers and online platforms increasingly control visibility.
- Regional and digital brands can gain customers rapidly; shoppers and retailers face low switching costs.
- Inflation in chemicals, plastic, packaging, energy and freight can reduce profit if retail price increases fail.
- Currencies have high influence on translated multinational sales; rates have moderate influence through consumer budgets and acquisition financing.
- Ingredient restrictions, claims standards, safety disputes and counterfeit goods can harm brand trust and require reformulation.
- Retailer concentration, promotions and private labels can absorb manufacturers’ price increases.
Bulls & bears
Can organic market-share gains and cash generation pay for the larger brand and aesthetics portfolio while litigation, promotion and financing costs rise?
Arguments
What to watch
- 1Divisional organic sales excluding IT order phasing, compared with the same markets
- 2Cash provided by operations, gross capex and debt after acquisitions
- 3Product-dispute expense, new rulings and any hair-relaxer provision
Next check: FY2026 financial statements for cash generation, litigation provisions and acquisition returns; track Mexico supply disruption and the Gucci transition due July1,2027, subject to approvals.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 83/100 by <a href="https://www.findmymoat.com/stocks/XPAR:OR">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.